| The inflammatory pathway of IL-17/IL-23 in the pathogenesis of spondyloarthritis: From geneticsusceptibility to enthesitis | Ahmet GÜL | 1–3 |
| New evidence and future in the adventure of spondyloarthritis | Ali İhsan ERTENLİ, Bayram FARİSOĞULLARI | 4–12 |
| The role of genetic and pro-inflammatory cytokines in the development of spondyloarthritis | Ender TERZİOĞLU, Bengisu ASLAN | 13–20 |
| Unmet needs in axial spondylarthritis: Focusing on Th-17 axis | İsmail SARI | 21–27 |
| Entheseal inflammation in SpA and new treatment modalities | Pamir ATAGÜNDÜZ | 28–31 |
| Low dose colchicine use in familial Mediterranean fever patients whose disease is under control | Nilüfer Alpay KANITEZ, Cemal BES, Selda ÇELİK, Sogol SADRİ, Emine AŞCI, Gamze ERGÜN, Ozan Cemal İÇAÇAN | 30–34 |
| Ankylosing spondylitis treatment | Ömer KARADAĞ, Bayram FARİSOĞULLARI | 32–45 |
| Evaluation of the follow-up and drug-related side effects of bosentan treatment for the treatment of systemic sclerosis related digital ulcer: a real life experience | Serdal UĞURLU, Mert ÖZTAŞ, Hamit ÖZGÜL | 35–38 |
| The evaluation of rheumatoid arthritis patients with knee and hip prosthesis: HURBIO biological registry | Abdülsamet ERDEN, İhsan ERTENLİ, Efe Cem ERDAT, Berkan ARMAĞAN, Umut Kalyoncu, Sedat KİRAZ, Alper SARI, Levent KILIÇ | 39–44 |
| Romatoid artrit hastalarında serum gebelikle ilişkili plazma protein-A düzeylerinin incelenmesi | Tahsin Murat TURGAY, Müçteba Enes YAYLA, Murat TORGUTALP, Gülay KINIKLI, Didem ŞAHİN EROĞLU, Serdar Sezer, Ayşe Bahar KELEŞOĞLU DİNÇER, Emine Gözde Aydemir GÜLÖKSÜZ, Aşkın ATEŞ, Özlem Ceylan DOĞAN | 45–50 |
| Treatment modalities in psoriatic arthritis | Umut KALYONCU, Emre BİLGİN | 46–53 |
| The frequency and reasons of non-attendance of patients to their appointments at a rheumatology outpatient clinic | Muhammet ÇINAR, Emre TEKGÖZ, Sedat YILMAZ, Seda ÇOLAK | 51–56 |